Moderna, an American pharmaceutical company, announced on the 28th that it has applied to the FDA = US Food and Drug Administration for an emergency use of the new coronavirus vaccine for children aged 6 months to under 6 years of age.
On the 28th, Moderna applied to the FDA for an emergency use authorization for this age group, saying that clinical trials of the new coronavirus vaccine in children aged 6 months to under 6 years have confirmed its efficacy and safety. Was announced.
In this age group, one-quarter of adults over the age of 18 will be inoculated twice.
According to Moderna, clinical trials of approximately 6,700 children between the ages of 6 months and 6 years have shown that the levels of antibodies that suppress the virus's activity after vaccination have increased to the same extent as in adults. That is.
In addition, the infection-preventing effect examined when the Omicron strain was widespread was 51% for those aged 6 months to under 2 years old and 37% for those aged 2 years to under 6 years old.
Regarding safety, the effects on health after vaccination tended to be the same as those of adults, and no new concerns were raised.
Moderna vaccination is now officially approved in the United States for people over the age of 18, and applications for emergency use permits are underway for other age groups as well.